arcadia biosciences (nasdaq: rkda) develops and markets high-value food ingredients and nutritional oils that help meet consumer demand for a healthier diet. arcadia’s goodwheat™ branded ingredients deliver health benefits to consumers and enable consumer packaged goods companies to differentiate their brands in the marketplace. the company’s portfolio of agricultural traits are being developed to enable farmers around the world to be more productive and minimize the impact of agriculture on the environment. for more information visit www.arcadiabio.com.
Company profile
Ticker
RKDA
Exchange
Website
CEO
Matthew T. Plavan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
RKDA stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
28 Mar 24
8-K
Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2023 Financial Results and Business Highlights
28 Mar 24
8-K
Departure of Directors or Certain Officers
14 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Arcadia Biosciences (RKDA) Announces Strong Third Quarter 2023
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Arcadia Biosciences (RKDA) Announces Second-Quarter and First-Half 2023 Financial Results and Business Highlights
10 Aug 23
8-K
Arcadia Biosciences (RKDA) Announces Strategic Review
20 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
12 Jun 23
S-8
Registration of securities for employees
25 May 23
Transcripts
RKDA
Earnings call transcript
2023 Q4
28 Mar 24
RKDA
Earnings call transcript
2023 Q3
9 Nov 23
RKDA
Earnings call transcript
2023 Q2
10 Aug 23
RKDA
Earnings call transcript
2023 Q1
11 May 23
RKDA
Earnings call transcript
2023 Q1
11 May 23
RKDA
Earnings call transcript
2022 Q4
30 Mar 23
RKDA
Earnings call transcript
2022 Q3
10 Nov 22
RKDA
Earnings call transcript
2022 Q2
12 Aug 22
RKDA
Earnings call transcript
2022 Q1
12 May 22
RKDA
Earnings call transcript
2021 Q4
30 Mar 22
Latest ownership filings
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
4
Thomas J. Schaefer
5 Feb 24
SC 13G
SABBY MANAGEMENT, LLC
3 Jan 24
4
Thomas J. Schaefer
7 Aug 23
4
Deborah D Carosella
16 Jun 23
4
Amy Yoder
16 Jun 23
4
Albert D. Bolles
16 Jun 23
4
GREGORY D WALLER
16 Jun 23
4
Lilian Shackelford Murray
16 Jun 23
4
Kevin Comcowich
16 Jun 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 10.61 mm | 10.61 mm | 10.61 mm | 10.61 mm | 10.61 mm | 10.61 mm |
Cash burn (monthly) | 957.67 k | 1.01 mm | 1.08 mm | 1.71 mm | 961.67 k | 1.13 mm |
Cash used (since last report) | 6.51 mm | 6.86 mm | 7.35 mm | 11.64 mm | 6.54 mm | 7.67 mm |
Cash remaining | 4.10 mm | 3.75 mm | 3.26 mm | -1.03 mm | 4.07 mm | 2.95 mm |
Runway (months of cash) | 4.3 | 3.7 | 3.0 | -0.6 | 4.2 | 2.6 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 13 |
Opened positions | 0 |
Closed positions | 3 |
Increased positions | 3 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 539.13 mm |
Total shares | 2.32 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Moral Compass | 1.13 mm | $0.00 |
Intracoastal Capital | 1.06 mm | $1.10 mm |
Sabby Management | 118.21 k | $458.67 mm |
STT State Street | 12.15 k | $47.13 mm |
UBS UBS Group AG - Registered Shares | 5.01 k | $19.44 mm |
Tower Research Capital | 2.93 k | $11.38 mm |
MS Morgan Stanley | 213.00 | $826.00 k |
Group One Trading | 104.00 | $404.00 k |
BLK Blackrock | 38.00 | $147.00 k |
USB U.S. Bancorp. | 5.00 | $19.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Aug 23 | Thomas J. Schaefer | Common Stock | Buy | Acquire P | No | No | 3.67 | 649 | 2.38 k | 719 |
6 Jun 23 | Comcowich Kevin | Stock Option Common Stock | Grant | Acquire A | No | No | 4.8 | 2,186 | 10.49 k | 5,587 |
6 Jun 23 | Murray Lilian Shackelford | Stock Option Common Stock | Grant | Acquire A | No | No | 4.8 | 937 | 4.50 k | 2,378 |
6 Jun 23 | Waller Gregory D | Stock Option Common Stock | Grant | Acquire A | No | No | 4.8 | 937 | 4.50 k | 2,429 |
6 Jun 23 | Bolles Albert D. | Stock Option Common Stock | Grant | Acquire A | No | No | 4.8 | 937 | 4.50 k | 2,485 |
News
HC Wainwright & Co. Reiterates Buy on Arcadia Biosciences, Maintains $10 Price Target
5 Apr 24
Recap: Arcadia Biosciences Q4 Earnings
28 Mar 24
Arcadia Biosciences Q4 EPS $(2.10) Beats $(2.58) Estimate, Sales $1.17M Miss $1.75M Estimate
28 Mar 24
Earnings Scheduled For March 28, 2024
28 Mar 24
Earnings Outlook For Arcadia Biosciences
27 Mar 24